An observational study in Charcot-Marie-Tooth and Hereditary Peripheral Neuropathy, sponsored by Centre Hospitalier Universitaire de Nice. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Centre Hospitalier Universitaire de Nice · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Charcot-Marie-Tooth Disease with a site in France — 7 open to participants now, 11 under way, 2 of them phase 3. Charcot-Marie-Tooth Disease · France.
Among the 24 studies in Charcot-Marie-Tooth Disease with a site in France, this one is one of 6 that started in 2026, is one of 7 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 24th registered.
114 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 38 are open to participants now.
Browse Charcot-Marie-Tooth Disease studies →7 of the 24 studies in Charcot-Marie-Tooth Disease with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 4+
Institut de Myologie, France · Sites in France
Ages 18–65 · Healthy volunteers
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
UGECAM PACA et Corse · Sites in France
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 31 Charcot-Marie-Tooth Disease studies recruiting now, 14 (45%) set no upper age limit and 13 (42%) stop at 75 or younger; 14 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 125 across 48 observational studies indexed under Charcot-Marie-Tooth Disease.
Median enrollment 67 across the 17 interventional studies, 60 across the 7 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 24 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nice is the lead sponsor of 724 studies on the registry; 177 are open to participants now.
Centre Hospitalier Universitaire de Nice has 3 studies filed under Charcot-Marie-Tooth Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Charcot-Marie-Tooth Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07940101Centre Hospitalier Universitaire de NiceClinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease | 2026-12-01 |
| NCT07321977Institut de Myologie, FranceAssessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers | 2026-12-31 |
| NCT07591779University Hospital, LimogesPhysical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment | 2027-04-15 |
| NCT02596191Assistance Publique Hopitaux De MarseilleTools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers | 2027-05-05 |
| NCT06845644Assistance Publique Hopitaux De MarseilleLongitudinal Quantitative Neuromuscular MRI in Neuropathic Patients | 2027-05-23 |
Add all 7 to your calendar (.ics) → With an account.
Among the 24 studies in Charcot-Marie-Tooth Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CMT-PROFILE is a single-center, cross-sectional observational study involving adults with Charcot-Marie-Tooth disease (CMT). The study will investigate the association between clinical disease severity, measured using the CMT Examination Score version 2 (CMTES-v2), and motor electrophysiological parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities. Secondary objectives include characterizing clinical-electrophysiological concordance, comparing functional capacity, muscle strength and mobility across concordance groups, and exploring demographic, clinical, biological and genetic factors associated with variability in disease expression. Approximately 250 patients are planned for inclusion. All assessments will be performed at a single reference time point (M0), with no longitudinal follow-up.
Adults with Charcot-Marie-Tooth disease evaluated at the Peripheral Neuromuscular Rare Disease Reference Center of Nice University Hospital. The study aims to characterize the relationships between clinical disease severity, assessed using the CMTES-v2, motor electrophysiological parameters, and functional capacity. Participants will undergo a single reference assessment (M0), with no subsequent follow-up. The planned sample size is approximately 250 participants, subject to confirmation against the approved protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: No intervention
This observational, cross-sectional study evaluates clinical severity, electrophysiological parameters, and functional capacity in adults with Charcot-Marie-Tooth disease (CMT). Data collected at a single reference time point (M0) include the CMT Examination Score version 2 (CMTES-v2), nerve conduction study parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities, and available functional and clinical measures. Additional variables may include muscle strength, mobility, pain, patient-perceived disease severity, occupational impact, and demographic, clinical, and genetic characteristics, as specified in the study protocol. No study-specific treatment or intervention is administered. There is no longitudinal follow-up
Association Between CMTES-v2 and Motor Electrophysiological Parameters
To assess the association between the CMTES-v2 total score and prespecified motor electrophysiological parameters, including distal CMAP amplitudes and motor nerve conduction velocities, using correlation analyses as specified in the statistical analysis plan.
Time frame: At day 0 (single assessment; no follow-up).
Clinical-Electrophysiological Concordance and Discordance Classification
disease severity and electrophysiological impairment, using standardized residuals derived from the difference between observed CMTES-v2 scores and scores predicted from motor electrophysiological parameters, divided by the residual standard deviation. Patients will be classified into three mutually exclusive categories: concordant (standardized residual between -1.96 and +1.96), greater clinical severity than predicted (standardized residual above +1.96), or lower clinical severity than predicted (standardized residual below -1.96). Results will be expressed as the number and percentage of patients in each category.
Time frame: At Day 0 (single assessment; no follow-up).
Age at Assessment Across Clinical-Electrophysiological Concordance Groups
To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups.
Time frame: At Day 0 (single assessment; no follow-up)
Age at Symptom Onset Across Clinical-Electrophysiological Concordance Groups
To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups.
Time frame: At Day 0 (single assessment; no follow-up)
Disease Duration Across Clinical-Electrophysiological Concordance Groups
To evaluate the relationship between disease duration and clinical-electrophysiological concordance, disease duration will be calculated as the interval, expressed in years, between the reported onset of symptoms and the reference clinical assessment. Disease duration will be compared across the three predefined concordance groups.
Time frame: At Day 0 (single assessment; no follow-up)
Genetic Subtype Distribution Across Clinical-Electrophysiological Concordance Groups
To investigate whether the distribution of genetically confirmed Charcot-Marie-Tooth disease subtypes differs according to clinical-electrophysiological concordance, genetic subtypes documented in the medical records will be categorized and compared across the three predefined concordance groups. Results will be reported as the number and percentage of patients within each genetic subtype among those with available genetic data.
Time frame: At Day 0 (single assessment; no follow-up)
Functional Performance Across Clinical-Electrophysiological Concordance Groups (CMT-FOM)
To evaluate whether functional performance differs according to clinical-electrophysiological concordance, functional capacity will be quantified using the total score of the Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Scores will be compared across the three predefined concordance groups among patients with available assessments.
Time frame: At Day 0 (single assessment; no follow-up).
Muscle Strength Across Clinical-Electrophysiological Concordance Groups (MRC Scale)
To assess differences in muscle strength according to clinical-electrophysiological concordance, muscle strength will be evaluated using the Medical Research Council (MRC) grading scale, ranging from 0 (no visible or palpable muscle contraction) to 5 (normal muscle strength). Recorded muscle strength grades will be compared across the three predefined concordance groups.
Time frame: At Day 0 (single assessment; no follow-up)
Right Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
To assess differences in right handgrip strength according to clinical-electrophysiological concordance, right handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups.
Time frame: At Day 0 (single assessment; no follow-up)
Left Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
To assess differences in left handgrip strength according to clinical-electrophysiological concordance, left handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups.
Time frame: At Day 0 (single assessment; no follow-up).
Functional Mobility Across Clinical-Electrophysiological Concordance Groups (Timed Up and Go)
To investigate differences in functional mobility according to clinical-electrophysiological concordance, mobility will be assessed using the Timed Up and Go (TUG) test, measuring the time required to rise from a chair, walk three meters, turn, return to the chair and sit down. Completion time will be recorded in seconds and compared across the three predefined concordance groups. Inability to complete the test safely will be recorded as a non-feasible assessment rather than assigned an arbitrary completion time.
Time frame: At Day 0 (single assessment; no follow-up)
Pain Intensity Across Clinical-Electrophysiological Concordance Groups
To investigate whether pain intensity differs according to clinical-electrophysiological concordance, average pain intensity over the preceding seven days will be assessed using an 11-point numerical rating scale, ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be compared across the three predefined concordance groups.
Time frame: At Day 0 (single assessment; no follow-up).
Patient-Perceived Disease Severity Across Clinical-Electrophysiological Concordance Groups
To evaluate differences in patient-perceived disease severity according to clinical-electrophysiological concordance, overall disease severity will be self-rated using a five-point ordinal scale ranging from 1 (very mild) to 5 (very severe). Scores will be compared across the three predefined concordance groups.
Time frame: At Day 0 (single assessment; no follow-up)
Work Absenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
To investigate differences in work absenteeism associated with Charcot-Marie-Tooth disease according to clinical-electrophysiological concordance, absenteeism will be assessed using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) and quantified as the percentage of working time missed due to the disease during the preceding seven days, ranging from 0% to 100%. Comparisons will be performed across the three predefined concordance groups among employed participants for whom the measure is applicable.
Time frame: At Day 0 (single assessment; no follow-up)
Work Presenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
To investigate differences in work-related productivity impairment while present at work according to clinical-electrophysiological concordance, presenteeism will be assessed using the WPAI:SHP questionnaire and expressed as the percentage of impairment while working attributable to Charcot-Marie-Tooth disease during the preceding seven days, ranging from 0% to 100%. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable.
Time frame: At Day 0 (single assessment; no follow-up).
Overall Work Productivity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
To assess whether overall work productivity impairment differs according to clinical-electrophysiological concordance, overall impairment will be calculated from the absenteeism and presenteeism components of the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable
Time frame: At Day 0 (single assessment; no follow-up).
Daily Activity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
To assess differences in the impact of Charcot-Marie-Tooth disease on usual daily activities according to clinical-electrophysiological concordance, activity impairment will be quantified using the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups, irrespective of employment status
Time frame: At Day 0 (single assessment; no follow-up)
Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice →